Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ADC Therapeutics SA
< Previous
1
2
3
Next >
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
April 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
April 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
April 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 13, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
March 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
March 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Provides Business Updates
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 06, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
November 02, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
October 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in September Investor Conferences
September 05, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
August 30, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
July 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 20, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 11, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
June 09, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
May 11, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
May 09, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
May 02, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
March 15, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.